{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-066825","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.164263+00:00","generated_at":"2026-06-04T22:23:55.635441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spero Therapeutics reports Q4 2023 net income of $51.2M; SPR720 topline data expected 2H 2024","bullets":["Q4 2023 net income of $51.2M ($0.96 diluted EPS) vs $26.8M in Q4 2022; full-year net income of $22.8M ($0.43 diluted EPS).","Total revenue $73.5M in Q4 2023, up from $47.4M in Q4 2022, driven by $71.8M in GSK/Pfizer collaboration revenue.","Cash and cash equivalents $76.3M at Dec 31, 2023; received $23.8M first tranche of $95M GSK milestone, expects cash runway into late 2025.","SPR720 Phase 2a proof-of-concept topline data in NTM-PD expected in second half of 2024; Phase 3 PIVOT-PO trial for tebipenem HBr enrolling.","Sath Shukla transitioned to President & CEO in August 2023; Esther Rajavelu appointed CFO/CBO in November 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-066825","json":"https://secwatch.observer/filing/0001193125-24-066825.json","markdown":"https://secwatch.observer/filing/0001193125-24-066825.md","text":"https://secwatch.observer/filing/0001193125-24-066825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/0001193125-24-066825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/d809069d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:23:55.635441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f02bf79bfadded93774c93b64bfb3526a19b9ac","claim":"Spero Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the ye, EPS $0.96 and $0.43.","evidence_excerpt":"Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the year ended December 31, 2023, or a diluted net income per share of common stock of $0.96 and $0.43, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/0001193125-24-066825-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the ye"},{"label":"EPS","value":"$0.96 and $0.43"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}